PHOEBUS is a Phase 2b randomized placebo-controlled trial investigating MaaT033 as an adjunctive therapy to improve 12-month overall survival rates for allogeneic hematopoietic stem cell transplant (allo-HSCT) patients MaaT033, the Company’s second drug candidate, is a donor-derived full microbiome ecosystem capsule applicable for ambulatory care Lyon, France, November 6, 2023 –7:30 am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of